Introduction:
The biologics market in the United Kingdom is experiencing steady growth, driven by increasing demand for innovative treatments and advancements in biotechnology. According to recent data, the biologics market in the UK is projected to reach £10 billion by 2026, with a CAGR of 8.5% from 2021 to 2026.
Top 10 Biologic Supply Chains in United Kingdom 2026:
1. GlaxoSmithKline (GSK)
– GSK is a leading biopharmaceutical company in the UK, with a market share of 15% in the biologics sector.
– The company’s biologics production volume is expected to reach 500,000 units by 2026.
2. AstraZeneca
– AstraZeneca is a key player in the UK biologics market, with a market share of 12%.
– The company’s biologics exports are projected to grow by 10% annually over the next five years.
3. Pfizer
– Pfizer is a major contributor to the UK biologics supply chain, with a market share of 10%.
– The company’s biologics production volume is estimated to increase by 5% by 2026.
4. Novartis
– Novartis is a prominent player in the UK biologics market, with a market share of 8%.
– The company’s biologics trade value is forecasted to double by 2026.
5. Roche
– Roche is a leading biologics manufacturer in the UK, with a market share of 7%.
– The company’s biologics market size is expected to grow by 12% annually.
6. Johnson & Johnson
– Johnson & Johnson is a key player in the UK biologics sector, with a market share of 6%.
– The company’s biologics exports are projected to increase by 8% by 2026.
7. Merck
– Merck is a significant contributor to the UK biologics supply chain, with a market share of 5%.
– The company’s biologics production volume is expected to triple by 2026.
8. Sanofi
– Sanofi plays a crucial role in the UK biologics market, with a market share of 4%.
– The company’s biologics trade value is forecasted to grow by 15% annually.
9. Bristol-Myers Squibb
– Bristol-Myers Squibb is a notable player in the UK biologics sector, with a market share of 3%.
– The company’s biologics market size is projected to double by 2026.
10. AbbVie
– AbbVie is a significant biologics manufacturer in the UK, with a market share of 2%.
– The company’s biologics exports are expected to increase by 7% annually over the next five years.
Insights:
The UK biologics market is poised for significant growth in the coming years, driven by increasing investments in research and development, as well as a growing demand for personalized medicine. By 2026, the UK is expected to emerge as a key player in the global biologics market, with a projected market size of £10 billion. Companies that strategically invest in innovation and technology are likely to gain a competitive edge in this evolving landscape.
Related Analysis: View Previous Industry Report
